Innate Pharma SA (IPHA) stock
IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
$1.59+0.05 (+3.25%)
Close on Nov 11, 2026Market cap $149.01MP/E –Yield –
Innate Pharma EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -0.55 EUR. The highest annual figure on record is 0.05 EUR in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -0.55 EUR | – |
| FY2024 | Dec 31, 2024 | -0.61 EUR | – |
| FY2023 | Dec 31, 2023 | -0.09 EUR | – |
| FY2022 | Dec 31, 2022 | -0.73 EUR | – |
| FY2021 | Dec 31, 2021 | -0.66 EUR | – |
| FY2020 | Dec 31, 2020 | -0.81 EUR | – |
| FY2019 | Dec 31, 2019 | -0.31 EUR | -720.0% |
| FY2018 | Dec 31, 2018 | 0.05 EUR | – |
| FY2017 | Dec 31, 2017 | -0.89 EUR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?